Another HIV vaccine failure: where to next?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).PloS one · 2016
   Trial
2. Regulation of the Cell Biology of Antigen Cross-Presentation.Annual review of immunology · 2018
   Review
3. Host Molecular Factors and Viral Genotypes in the Mother-to-Child HIV-1 Transmission in Sub-Saharan Africa.Journal of public health in Africa · 2017
   Review
4. Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies.Molecular therapy. Methods & clinical development · 2016
   Review
5. RNA Viruses and RNAi: Quasispecies Implications for Viral Escape.Viruses · 2015
   Review
6. HIV-1 vaccine immunogen design strategies.Virology journal · 2015
   Review
7. Genetic Consequences of Antiviral Therapy on HIV-1.Computational and mathematical methods in medicine · 2015
   Review
8. Effect of vaginal immunization with HIVgp140 and HSP70 on HIV-1 replication and innate and T cell adaptive immunity in women.Journal of virology · 2014
   Article
9. Designer antigens for elicitation of broadly neutralizing antibodies against HIV.Clinical & translational immunology · 2014
   Article
10. Mucosal vaccines against respiratory syncytial virus.Current opinion in virology · 2014
    Review

Corrections and comments

• Comment on
  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.2013

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as